EcoDrugPlus

Bcl2 Like 10

Ensembl ID : ENSPNAG00000022946
Gene Symbol: BCL2L10
3 Cross references
128 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSPNAG00000021082
Gene Symbol: BCR
3 Cross references
205 Possible Orthologues:

Bdnf/nt-3 Growth Factors Receptor-Like

Ensembl ID : ENSPNAG00000000301
Gene Symbol: LOC108443857
3 Cross references
210 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSPNAG00000018069
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSPNAG00000003379
Gene Symbol: LOC108442972
2 Cross references
193 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSPNAG00000008529
Gene Symbol: LOC108430266
3 Cross references
188 Possible Orthologues:

C-X-C Chemokine Receptor Type 1-Like

Ensembl ID : ENSPNAG00000007588
Gene Symbol: LOC108442715
2 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSPNAG00000010075
Gene Symbol: CXCR4
3 Cross references
201 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSPNAG00000013628
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

D(2)-Like Dopamine Receptor

Ensembl ID : ENSPNAG00000003365
Gene Symbol: LOC108428674
3 Cross references
141 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSPNAG00000022039
Gene Symbol: LOC108412785
3 Cross references
122 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSPNAG00000017177
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).